[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520365":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":29,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Institut Paoli-Calmettes","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DASATINIB","EXPERIMENTAL",null,[13],"Drug: Dasatinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Dasatinib","Daily orally administration of DASATINIB",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Jihane PAKARANOUNI, PharmD,PhD","CONTACT","+33491223778","drci.up@ipc.unicancer.fr",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":25},"Laurie-Anne GOUTY, PhD","33491223778",[30],{"facility":31,"status":32,"city":33,"state":11,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Institut Paoli Calmettes","RECRUITING","Marseille","France","FR",{"type":37,"coordinates":38},"Point",[39,40],5.38107,43.29695,{"lat":40,"lon":39},[43,46,47],{"name":44,"role":23,"phone":45,"phoneExt":11,"email":25},"Jihane PAKRADOUNI, Dr","0033491223778",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":25},{"name":48,"role":49,"phone":11,"phoneExt":11,"email":11},"Sylvain GARCIAZ, MD PhD","PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100520365","phase-2-evaluation-of-dasatinib-monotherapy-efficacy-in-acute-myeloid-leukemia-patients-refractory-to-venetoclax-azacitidine-100520365",false,"NCT06055621","Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE","Evaluation of DASATINIB Monotherapy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE","VEN-R DASA","Inclusion Criteria:\n\n* Confirmed diagnosis of AML except Philadelphia chromosome-positive AML (Ph+) and acute promyelocytic leukemia (AML M3)\n* Age ≥ 18 years\n* ECOG ≤3\n* VEN-AZA refractory defined as no response after two cycles of VEN-AZA whatever the dose and the treatment duration\n* Signed informed consent form\n* Affiliation to a social security system, or beneficiary of such a system\n\nExclusion Criteria:\n\n* Patient eligible to a targeted therapy having a market authorization\n* Central nervous system involvement\n* Heart failure\n* Liver failure\n* Kidney failure\n* Contraindication to DASATINIB\n* Positive for HIV (detectable viral load), Hepatitis B or C\n* Pregnant or breastfeeding woman\n* No efficient contraception for the women of childbearing age\n* Emergency situation person or not able to express his\u002Fher informed consent\n* Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice)\n* Inability to undergo the clinical trial medical follow-up for geographical, social or psychological reasons","ALL","18 Years",{"count":63,"type":64},35,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE. The main question it aims to answer is to assess the tumor response after 2 cycles of DASATINIB monotherapy treatment for patients with chemotherapy-ineligible acute myeloid leukemia refractory to VENETOCLAX-AZACITIDINE therapy.\n\nParticipants will be given DASATINIB treatment up to 3 months. Response will be assessed by a myelogram and a complete blood count at the end of every cycle. Follow up will last 6 months.",[70],"Acute Myeloid Leukemia","2026-03-11",{"date":73,"type":74},"2026-03-13","ACTUAL",{"date":76,"type":74},"2024-05-22",{"date":78,"type":64},"2027-10-31",{"name":5,"class":6},1]